About Us

We are a preclinical stage bio-pharmaceutical company located in Paris

We are mission-driven, dedicated to advancing medicine, improving patients’ health and saving lives

We have the ambition to become a leading player in the market of rare kidney diseases in both adults and children

We are first focused on the treatment of Crescentic Glomerulonephritis in adults, a severe condition with no effective treatment

The company is lead by a seasoned and complementary leadership team with more than 130 years of experience in successfully bringing products on the market.

Backed by renowed clinical leaders in renal medicine and a large access to patients network, DETERA Therapeutics is well-positioned to advance its mission.

Lyse SANTORO- PhD & Insead

Co-Founder & CEO

The Executive Team

Daniel GILLET- PhD

Co-Founder & CSO/COO

Pierre-Louis THARAUX- MD, PhD

Co-Founder & CMO

André ULMANN- MD, PhD

Business Angel, Successful Serial Entrepreneur

Sharesholders

Alongisde founding leadership team members Lyse Santoro, Daniel Gillet, Pierre-Louis Tharaux, additional shareholders also contribute to DETERA’s strategic vision.

A network of Key Opinion Leaders

Guided by Global Experts , we are proud to be supported by world-renowed Key Opinion Leaders in the field of rare kidney diseases, particularly those affecting the glomeruli such as CGN and the conditions we study. Their commitment and expertise strenghthen our mission and accelerate our path toward transformative therapties.

A network of clinicians

Embedded in Clinical Reality, we collaborate closely with clinicians who are actively involved in conducting clinical trials focused on the rare kidney diseases we study. Their ongoing engagement with patients ensures our research remains directly connected to clinical needs and enhances our ability to access relevant patient populations..